Suggested remit: To appraise the clinical and cost effectiveness of rimegepant within its marketing authorisation for treating or preventing migraine.
Status In progress
Technology type Medicine
Decision Selected
Process STA Standard
ID number 1539

Provisional Schedule

Expected publication 18 October 2023

Project Team

Project lead Celia Mayers

Email enquiries

External Assessment Group BMJ Technology Assessment Group (BMJ-TAG), BMJ


Companies sponsors Pfizer (rimegepant)
Others Department of Health and Social Care
  NHS England
  Welsh Government
Patient carer groups Migraine Trust
Professional groups Association of British Neurologists
  British Association for the Study of Headache
  British Pain Society
  Royal College of Physicians
  UK Clinical Pharmacy Association
Comparator companies AbbVie
  Accord Healthcare - not participating
  Advanz Pharma - not participating)
  Alliance Pharmaceuticals - not participating
  Aspire Pharma - not participating
  Aurobindo Pharma - not participating
  Baxter Healthcare - not participating
  Boots - not participating
  Bristol Laboratories - not participating
  Bristol Myers Squibb Pharmaceuticals - not participating
  Brown and Burk UK - not participating
  Cipla - not participating
  Dexcel-Pharma- not participating
  Dr Reddy's Laboratories UK - not participating
  Eli Lilly (galcanezumab)
  Fannin - not participating
  Flamingo Pharma UK - not participating
  Galderma - not participating
  Galen - not participating
  Genus Pharmaceuticals - not participating
  GlaxoSmithKline - not participating
  Glenmark Pharmaceuticals - not participating
  Grunenthal- not participating
  Healthcare Pharma - not participating
  Infirst Healthcare (i- not participating
  Intrapharm Laboratories - not participating
  Ipca Laboratories - not participating
  Janssen-Cilag - not participating
  Kent Pharmaceuticals - not participating
  M&A Pharmachem - not participating
  Martindale Pharmaceuticals- not participating
  McNeil Products - not participating
  Merz Pharma - not participating
  Mylan - not participating
  Neuraxpharm UK - not participating
  Novartis (erenumab)
  Omega Pharma - not participating
  Organon - not participating
  Pfizer (ibuprofen, eletriptan)
  Pinewood Healthcare - not participating
  Reckitt Benckisser Healthcare - not participating
  Rosemont Pharmaceuticals - not participating
  Sandoz - not participating
  Sanofi - not participating
  Sun Pharmaceuticals UK - not participating
  Teva UK Limited (fremanezumab)
  Thame Laboratories (- not participating
  Tillomed Laboratories - not participating)
  Trion Pharma - not participating
  Typharm - not participating
  UCB Pharma - not participating
  Wockhardt UK - not participating
  Zentiva UK - not participating
General commentators All Wales Therapeutics and Toxicology Centre
  British National Formulary
  Department of Health, Social Services and Public Safety for Northern Ireland
  Medicines and Healthcare products Regulatory Agency
  Scottish Medicines Consortium
  Welsh Health Specialised Services Committee


Key events during the development of the guidance:

Date Update
10 August 2023 Committee meeting: 3
31 May 2023 - 21 June 2023 Draft guidance
09 May 2023 Following the second committee meeting on 13 April 2023 for rimegepant for treating or preventing migraine [ID1539], this topic has been split into its 2 indications. Rimegepant for treating acute migraine will retain ID1539. Rimegepant for preventing episodic migraine will use ID6275.
13 April 2023 Committee meeting: 2
21 February 2023 - 14 March 2023 Draft guidance
19 January 2023 Committee meeting: 1
03 February 2022 Pfizer and Biohaven have entered into a commercialization arrangement and Pfizer will be leading on the reimbursement and commercialization activities for this technology in the UK. The scope for the appraisal has been updated accordingly and is available in the documents section of this topic page. The scope has also been amended to reflect the publication of updated NICE guidance on fremanezumab (TA764) following a rapid review. TA764 has replaced TA631.
04 November 2021 Based on communications with the company, Biohaven Pharma, the appraisal committee meeting for rimegepant originally planned for June 2022 will be rescheduled, and we will inform stakeholders of the new timeline for submission in due course.
22 September 2021 In progress. Invitation to Participate issued.
22 September 2021 Invitation to participate
09 September 2021 For information, the appraisal is now expected to start in approximately late September 2021 when we will write to consultees and commentators about how they can get involved.
15 April 2021 - 14 May 2021 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators

For further information on our processes and methods, please see our CHTE processes and methods manual